# MLF2

## Overview
MLF2 (myeloid leukemia factor 2) is a gene that encodes a protein of the same name, which plays a significant role in various cellular processes, including cell proliferation, survival, and signaling pathways. The MLF2 protein is categorized as a molecular chaperone and is involved in the assembly of multi-protein complexes, signal transduction, and endocytosis. It is ubiquitously expressed in human cells and functions in both the nucleus and cytoplasm, influencing transcriptional regulation and cellular stress responses (Kuefer1996cDNA; Yang2019The). The protein's activity is modulated by post-translational modifications, such as phosphorylation and ubiquitination, which are crucial for its role in promoting cell growth and proliferation, particularly in cancer contexts (Huang2020CRL4DCAF8; Yang2019The). MLF2's interactions with other proteins, such as those involved in the ubiquitin-proteasome pathway and nuclear envelope dynamics, underscore its involvement in maintaining cellular homeostasis and its potential implications in disease pathology (Banerjee2017Modulation; Prophet2021MLF2).

## Function
MLF2 (myeloid leukemia factor 2) is a protein involved in several critical cellular processes, including cell proliferation, survival, and signaling pathways. It is ubiquitously expressed in human cells and plays a role in cellular growth and differentiation (Kuefer1996cDNA). MLF2 is active in both the nucleus and cytoplasm, where it influences transcriptional regulation and cellular stress responses. It functions as a molecular chaperone involved in multi-protein complex assembly, signal transduction, and endocytosis (Yang2019The).

The phosphorylation of MLF2 at serine 24 is crucial for its activity, affecting its role in cell proliferation and survival. This post-translational modification is necessary for maintaining MLF2's function in promoting cell growth and proliferation, particularly in the context of cancer (Yang2019The). MLF2 is also involved in the PI3K/AKT signaling pathway, which is important for cell growth and survival (Yang2019The).

MLF2's stability is regulated through ubiquitination and deubiquitination processes. The CRL4 DCAF8 E3 ligase complex targets MLF2 for degradation, while USP11 stabilizes it by removing ubiquitin, highlighting a complex regulatory network that influences MLF2's function in cell biology (Huang2020CRL4DCAF8).

## Clinical Significance
MLF2 (myeloid leukemia factor 2) is implicated in various cancers, including chronic myeloid leukemia (CML) and breast cancer. In CML, MLF2 is overexpressed in bone marrow samples and K562 cells, suggesting its role in disease progression. This overexpression is associated with reduced sensitivity to imatinib, a common CML treatment, indicating that MLF2 may contribute to leukemogenesis and affect treatment outcomes (Yang2019The). Phosphorylation of MLF2 at serine 24 is crucial for its oncogenic activity in CML, with mutations at this site reducing its cancer-promoting effects (Yang2019The).

In breast cancer, MLF2 mutations such as D12H and F158W are linked to poor survival outcomes. The R158W mutation, in particular, is associated with more aggressive disease and a shorter time to metastasis (Liu2019Detection). MLF2 is also involved in the self-renewal of breast cancer stem cells, further implicating it in tumor initiation and metastasis (Yang2019The).

Alterations in MLF2 expression or mutations can contribute to tumorigenesis by affecting cell proliferation and apoptosis, highlighting its potential as a therapeutic target in these cancers (Huang2020CRL4DCAF8).

## Interactions
MLF2 (myeloid leukemia factor 2) is involved in various protein interactions that influence its function and stability. MLF2 interacts with the CRL4DCAF8 complex, which includes DCAF8, DDB1, CUL4B, and ROC1, promoting its degradation through the ubiquitin-proteasome pathway. Conversely, the deubiquitinating enzyme USP11 stabilizes MLF2 by reducing its ubiquitination, highlighting a regulatory mechanism that balances MLF2 levels in cells (Huang2020CRL4DCAF8).

In the context of nuclear envelope (NE) blebs, MLF2 recruits chaperones such as DNAJB6 and interacts with HSPA1A, particularly in Torsin-deficient cells. This interaction is crucial for the sequestration of these chaperones into NE blebs, which is associated with proteotoxicity in conditions like DYT1 dystonia (Prophet2021MLF2). MLF2 also interacts with FG-nucleoporins, facilitating phase separation and influencing the properties of NE condensates (Prophet2021MLF2).

Additionally, MLF2 has been shown to interact with mutant Huntingtin protein, reducing the formation of aggregates and apoptosis in cells, which suggests a potential therapeutic role in modulating Huntington's disease pathology (Banerjee2017Modulation). These interactions underscore MLF2's involvement in cellular processes related to protein homeostasis and disease pathology.


## References


[1. (Banerjee2017Modulation) Manisha Banerjee, Moumita Datta, and Nitai P. Bhattacharyya. Modulation of mutant huntingtin aggregates and toxicity by human myeloid leukemia factors. The International Journal of Biochemistry &amp; Cell Biology, 82:1–9, January 2017. URL: http://dx.doi.org/10.1016/j.biocel.2016.11.008, doi:10.1016/j.biocel.2016.11.008. This article has 14 citations.](https://doi.org/10.1016/j.biocel.2016.11.008)

[2. (Yang2019The) Juhua Yang, Donglin Cao, Yanrong Zhang, Ruiming Ou, Zhao Yin, Yanjun Liu, Guiping Huang, Chunming Gu, Shengting Chen, and Jia Fei. The role of phosphorylation of mlf2 at serine 24 in bcr-abl leukemogenesis. Cancer Gene Therapy, 27(1–2):98–107, December 2019. URL: http://dx.doi.org/10.1038/s41417-019-0152-4, doi:10.1038/s41417-019-0152-4. This article has 7 citations and is from a peer-reviewed journal.](https://doi.org/10.1038/s41417-019-0152-4)

3. (Prophet2021MLF2) MLF2 modulates phase separated nuclear envelope condensates that provoke dual proteotoxicity. This article has 2 citations.

[4. (Kuefer1996cDNA) Martin U. Kuefer, A.Thomas Look, Deanna C. Williams, Virginia Valentine, Clayton W. Naeve, Frederick G. Behm, Jerald E. Mullersman, Noriko Yoneda-Kato, Kate Montgomery, Raju Kucherlapati, and Stephan W. Morris. Cdna cloning, tissue distribution, and chromosomal localization of myelodysplasia/myeloid leukemia factor 2 (mlf2). Genomics, 35(2):392–396, July 1996. URL: http://dx.doi.org/10.1006/geno.1996.0376, doi:10.1006/geno.1996.0376. This article has 27 citations and is from a peer-reviewed journal.](https://doi.org/10.1006/geno.1996.0376)

[5. (Huang2020CRL4DCAF8) Daoyuan Huang, Cheng Liu, Xiwen Sun, Xinpei Sun, Yanan Qu, Yunyi Tang, Guodong Li, and Tanjun Tong. Crl4dcaf8 and usp11 oppositely regulate the stability of myeloid leukemia factors (mlfs). Biochemical and Biophysical Research Communications, 529(2):127–132, August 2020. URL: http://dx.doi.org/10.1016/j.bbrc.2020.05.186, doi:10.1016/j.bbrc.2020.05.186. This article has 7 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.bbrc.2020.05.186)

[6. (Liu2019Detection) Zhe-Bin Liu, Nader E. Ezzedine, Agda K. Eterovic, Joe E. Ensor, Helen J. Huang, Joan Albanell, Dong S. Choi, Ana Lluch, Yi Liu, Federico Rojo, Helen Wong, Eduardo Martínez-Dueñas, Ángel Guerrero-Zotano, Zhi-Min Shao, Jorge G. Darcourt, Gordon B. Mills, Bhuvanesh Dave, and Jenny C. Chang. Detection of breast cancer stem cell gene mutations in circulating free dna during the evolution of metastases. Breast Cancer Research and Treatment, 178(2):251–261, August 2019. URL: http://dx.doi.org/10.1007/s10549-019-05374-x, doi:10.1007/s10549-019-05374-x. This article has 15 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s10549-019-05374-x)